ImmuPharma plc (LON:IMM – Get Free Report) was up 30.8% on Friday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.43 ($0.04). Approximately 7,318,278 shares changed hands during trading, a decline of 68% from the average daily volume of 23,169,156 shares. The stock had previously closed at GBX 2.63 ($0.03).
ImmuPharma Stock Performance
The company has a market cap of £13.95 million, a PE ratio of -335.00 and a beta of 1.53. The company has a fifty day moving average of GBX 1.56 and a two-hundred day moving average of GBX 1.68.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What is the Dogs of the Dow Strategy? Overview and Examples
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Pros And Cons Of Monthly Dividend Stocks
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
